Skip to main content
Premium Trial:

Request an Annual Quote

GPC Expands Collaboration with Altana to Include Interaction Technology

NEW YORK, June 13 - GPC Biotech has expanded its collaboration with Altana Pharma to include its LeadCode yeast three-hybrid technology for studying protein-drug interactions, the company said yesterday.

 

Under the agreement, Munich-based GPC will receive payments for the license, transfer, and implementation of LeadCode at the Altana Research Institute in Waltham, Mass. GPC can also obtain royalties and more than $15 million in milestone payments for products that result from the collaboration with Constance, Germany-based Altana Pharma. GPC will use LeadCode to evaluate proprietary compounds provided by Altana Pharma as well as compounds from the public domain.

 

Altana Pharma and GPC Biotech started their five-and-a-half-year collaboration to establish the Altana Research Institute in November 2001. The companies have two other ongoing multi-year alliances, in cellular genomics and oncology.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.